Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
Journal Volume
36
Journal Issue
3
Pages
434
Date Issued
2022-03
Author(s)
Thyssen, J P
Yosipovitch, G
Paul, C
Kwatra, S G
DiBonaventura, M
Feeney, C
Zhang, F
Myers, D
Rojo, R
Valdez, H
Abstract
In JADE COMPARE, abrocitinib improved severity of atopic dermatitis (AD) and demonstrated rapid itch relief.
Subjects
ORIENTED ECZEMA MEASURE; PLACEBO; ADOLESCENTS; VALIDATION; DUPILUMAB; SYMPTOMS; INDEX; LIFE
Publisher
WILEY
Type
journal article